시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 의료용 아이소토프 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 최종사용자별, 용도별, 지역별 전망 및 예측(2023-2030년)
Global Medical Isotope Market Size, Share & Trends Analysis Report By Type, By End User (Hospitals, Diagnostic Centers, and Research Institutes), By Application (Diagonostic, and Nuclear Therapy), By Regional Outlook and Forecast, 2023 - 2030
상품코드 : 1448153
리서치사 : KBV Research
발행일 : 2024년 03월
페이지 정보 : 영문 202 Pages
 라이선스 & 가격 (부가세 별도)
US $ 3,600 ￦ 5,197,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,320 ￦ 6,237,000
PDF (Multi User License) help
PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,048 ￦ 8,732,000
PDF (Corporate User License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계 의료용 아이소토프 시장 규모는 2030년까지 91억 달러에 달할 것으로 예상되며, 예측 기간 동안 8.6%의 연평균 복합 성장률(CAGR)를 나타낼 전망입니다.

또한, 암이나 심혈관 질환의 경우 질병의 정도, 병기, 진행을 평가하기 위해 종합적인 진단 평가가 필요한 경우가 많습니다. 테크네튬-99m(Tc-99m) 및 불소-18(F-18)과 같은 의료용 아이소토프는 PET 및 단광자 방출 컴퓨터 단층 촬영(SPECT)과 같은 핵의학 영상 기술에 널리 사용되어 생리적 과정을 시각화하고 질병과 관련된 이상을 식별합니다. 따라서 암 및 심혈관 질환 사례 증가가 시장 성장을 주도하고 있습니다.

그러나 핵의학 영상 처리 및 치료에 사용되는 방사성 동위원소는 대부분 원자로에서 생성되며, 고도로 전문화된 인프라와 규제 감시가 필요합니다. 방사성 동위원소의 가용성은 원자로의 가동 상태에 따라 달라지며, 유지보수 중단, 규제 검사 및 안전 프로토콜의 적용을 받을 수 있습니다. 따라서 방사성 동위원소의 가용성이 제한적이라는 점이 시장 성장을 저해하는 요인으로 작용하고 있습니다.

또한, 여행 제한, 봉쇄 조치, 원자로 및 동위원소 생산 시설의 인력 감축으로 인해 의료용 아이소토프 확보가 지연되거나 부족하여 환자 치료 및 진단 절차에 영향을 미쳤습니다. 팬데믹이 절정에 달했을 때, 코로나19 환자를 위한 자원을 우선시하기 위해 영상진단 및 핵의학 스캔과 같은 많은 불필요한 의료 절차가 연기되거나 취소되었습니다. 이처럼 코로나19 사태는 시장에 부정적인 영향을 미쳤습니다.

목차

제1장 시장 범위와 조사 방법

제2장 시장 요람

제3장 시장 개요

제4장 의료용 아이소토프 시장에서 전개되고 있는 최근 전략

제5장 세계 시장 : 유형별

제6장 세계 시장 : 최종사용자별

제7장 세계 시장 : 용도별

제8장 세계 시장 : 지역별

제9장 기업 개요

제10장 의료용 아이소토프 시장을 위한 성공 필수 조건

LSH
영문 목차

영문목차

The Global Medical Isotope Market size is expected to reach $9.1 billion by 2030, rising at a market growth of 8.6% CAGR during the forecast period.

The development of new therapeutic radiopharmaceuticals and expanded clinical indications for existing isotopes has led to a growing number of therapeutic procedures in nuclear medicine. Consequently, the nuclear therapy segment would generate approximately 24.2 % share of the market by 2030. Research and clinical trials continue to explore the efficacy and safety of isotopic therapies for a wide range of medical conditions, including bone metastases, neuroendocrine tumors, thyroid disorders, and hematological malignancies.

Nuclear medicine imaging technology advances have significantly improved image quality, resolution, and sensitivity. High-resolution imaging systems, such as PET/CT and SPECT/CT scanners, provide detailed anatomical and functional information, allowing healthcare professionals to visualize physiological processes at the molecular level with exceptional clarity. Therefore, advancements in nuclear medicine imaging techniques drive the market's growth.

Additionally, Cancer and cardiovascular diseases often require comprehensive diagnostic evaluation to assess disease extent, stage, and progression. Medical isotopes, such as technetium-99m (Tc-99m) and fluorine-18 (F-18), are widely used in nuclear medicine imaging techniques such as PET and single-photon emission computed tomography (SPECT) to visualize physiological processes and identify disease-related abnormalities. Therefore, the rising cases of cancer and cardiovascular diseases are driving the growth of the market.

However, Many radioisotopes used in nuclear medicine imaging and therapy are produced in nuclear reactors, which require highly specialized infrastructure and regulatory oversight. Radioisotope availability depends on the operational status of nuclear reactors, which may be subject to maintenance shutdowns, regulatory inspections, and safety protocols. Hence, the limited availability of radioisotopes is hampering the market's growth.

Furthermore, Restrictions on travel, lockdown measures, and reduced staffing at nuclear reactors and isotope production facilities led to delays and shortages in the availability of medical isotopes, impacting patient care and diagnostic procedures. During the peak of the pandemic, many non-essential medical procedures, including diagnostic imaging and nuclear medicine scans, were postponed, or canceled to prioritize resources for COVID-19 patients. Thus, the COVID-19 pandemic had a negative impact on the market.

By Type Analysis

On the basis of type, the market is segmented into stable isotopes and radioisotopes. The radioisotopes segment recorded the 73.57 % revenue share in the market in 2022. Radioisotopes, drugs, or compounds labeled with radioactive isotopes for diagnostic purposes are essential for radiopharmaceuticals. Radioisotopes such as technetium-99m (Tc-99m), gallium-68 (Ga-68), and copper-64 (Cu-64) are commonly incorporated into radiopharmaceutical formulations for clinical use. Hence, higher demand for radiopharmaceuticals is driving the growth of the segment.

By End User Analysis

Based on end user, the market is categorized into hospitals, diagnostic centers, and research institutes. The diagnostic centers segment witnessed a 28.92 % revenue share in the market in 2022. Diagnostic centers facilitate multidisciplinary collaboration among healthcare professionals, including radiologists, nuclear medicine physicians, oncologists, surgeons, and medical physicists. Diagnostic centers are hubs for collaboration and communication, fostering teamwork and care coordination across different specialties.

By Application Analysis

Based on application, the market is bifurcated into diagnostic and nuclear therapy. The diagnostic segment attained the 75.79 % revenue share in the market in 2022. Diagnostic imaging plays a crucial role in the early detection and diagnosis of various medical conditions, including cancer, cardiovascular diseases, neurological disorders, and musculoskeletal injuries. Medical isotopes enable the development of highly sensitive and specific imaging techniques that facilitate the early detection of abnormalities and disease processes at the cellular and molecular levels.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region generated a 26.87 % revenue share in the market. The Asia Pacific region is experiencing a rise in the incidence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. As the burden of disease increases, there is a greater need for early detection, accurate diagnosis, and effective treatment options, driving demand for diagnostic imaging studies and therapeutic interventions using medical isotopes.

Recent Strategies Deployed in the Market

List of Key Companies Profiled

Global Medical Isotope Market Report Segmentation

By Type

By End User

By Application

By Geography

Table of Contents

Chapter 1.Market Scope & Methodology

Chapter 2.Market at a Glance

Chapter 3.Market Overview

Chapter 4.Recent Strategies Deployed in Medical Isotopes Market

Chapter 5.Global Medical Isotope Market by Type

Chapter 6.Global Medical Isotope Market by End User

Chapter 7.Global Medical Isotope Market by Application

Chapter 8.Global Medical Isotope Market by Region

Chapter 9.Company Profiles

Chapter 10.Winning Imperatives of medical isotopes Market

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기